Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Amphivena Therapeutics" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Amphivena Therapeutics for you to read. Along with our medical data and news we also list Amphivena Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Amphivena Therapeutics Companies for you to search.
Data Demonstrate AMV564’s Safety, Anti-Leukemic Activity, and Unique PK Profile Amphivena Therapeutics, Inc., a privately held biotechnology company developing AMV564, a CD33/CD3 T cell engager for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), presented Saturday night in a poster presentation at the 60th Annual ...
#ASH18 anti-CD33 agents for AML $AMGN '330 BiTE https://ash.confex.com/ash/2018/webprogram/Paper109762.html … Amphivena AMV564 bi-spec https://ash.confex.com/ash/2018/webprogram/Paper111529.html … $JAZZ $IMGN '779 ADC https://ash.confex.com/ash/
#ASH18 anti-CD33 agents for AML $AMGN '330 BiTE https://ash.confex.com/ash/2018/webprogram/Paper109762.html … Amphivena AMV564 bi-spec https://ash.confex.com/ash/2018/webprogram/Paper111529.html … $JAZZ $IMGN '779
Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CEO The post Roche’s Genentech agrees to buy Jecure Therapeutics appeared first on Pharmaceutical Business review.
The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. Specific The post HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics appeared first on Pharma Business review.
Indalo Therapeutics has appointed Robert Jacks to serve as president and CEO. Jacks was most recently president and chief financial officer of Symbiomix Therapeutics, which was acquired by Lupin in 2017. Indalo was formed by the 2016 merger of Antegrin Therapeutics and Cascadia Therapeutics. The Cambridge, MA-based company’s lead drug candidate, IDL-2965, is expected to […]
Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng). Existing investor Lilly Asian Ventures (LAV)...Read More... The post Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics appeared first on Drug Development Technology.
Hoth Therapeutics Inc. (technology that creates a topical agent from existing therapeutics to treat skin diseases) filed for ...
HiFiBio Therapeutics acquired French biotech H-Immune Therapeutics, a privately held firm developing immuno-oncology therapie...
20 - 21 February 2019, London, UK. Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.
Under the agreement, the two companies will use e-therapeutics’ network-driven drug discovery platform for the identification of new therapeutics approaches to treat Type 2 diabetes, which currently accounts The post e-therapeutics, Novo Nordisk enter into research collaboration deal appeared first on Pharmaceutical Business review.
Summit Therapeutics plc('Summit', or the 'Company')Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceOxford, UK, and Cambridge, MA, US, 6 August 2018 - Summit Therapeutics p...
Ionis Pharmaceuticals affiliate Akcea Therapeutics has signed an agreement with biopharmaceutical company PTC Therapeutics for the commercialisation of its rare...Read More... The post PTC Therapeutics to commercialise Akcea’s two rare disease drugs appeared first on Pharmaceutical Technology.
NEW YORK und CLEVELAND, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), ein führendes, in der klinischen Erprobung tätiges Biopharmaunternehmen, das sich auf die Entwickl...
On September 5, speakers at the Microbiome Therapeutics US conference shed light on the future of microbiome therapeutics, which is...Read More... The post From Parkinson’s to asthma: opportunities for microbiome-based therapeutics appeared first on Pharmaceutical Technology.
NEW YORK und CLEVELAND (USA), Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), ein führendes in der klinischen Erprobung tätiges Biopharma unternehmen, das sich auf die En...
BOSTON and LONDON, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with s...
NEW YORK and CLEVELAND, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene thera...
Telefonkonferenz für Anleger am Montag, 12. November, um 10.00 Uhr ET (amerikanische Ostküstenzeit) NEW YORK und CLEVELAND, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ: ABEO)...
4D Molecular Therapeutics snagged $90 million in a Series B financing round. The company intends to use the funds to advance its Therapeutic Vector Evolution platform and pipeline of next-generation AAV gene therapeutics.
PHILADELPHIA, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
Tusk Therapeutics to be acquired by Roche Stevenage, United Kingdom - September 28th 2018: Tusk Therapeutics Ltd ("Tusk") was today acquired by Roche. Tusk has developed an antibody with a novel m...
Investor Conference Call on Monday, November 12th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biophar...
Novo Nordisk has signed a deal with UK biotech e-Therapeutics to use its AI-based drug discovery technology to find new therapies for type 2 diabetes. e-Therapeutics will work with Novo for a year and use its technology to identify novel intervent...
NANOGAP Therapeutics CEO Ross Breckenridge joined Proactive Investors at the 11th Annual BioTech Showcase in San Francisco. The company is a seed level company developing therapeutics to combat a mutant gene in cancers called KRAS.
NEW YORK and CLEVELAND, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for se...